SCHEMBL2483568

SCHEMBL2483568

CC(c1ccccc1)C(O)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.62
LMNA P02545 3/20 0.62
ADRA2C P18825 2/20 0.62
ADRA2A P08913 1/20 0.62
HIF1A Q16665 1/20 0.62
ALDH1A1 P00352 3/20 0.60
CHRM2 P08172 1/20 0.58
ADRA1A P35348 1/20 0.58
RGS12 O14924 1/20 0.58
GLA P06280 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
PKM P14618 1/20 0.58
ALOX15 P16050 1/20 0.58
TSHR P16473 1/20 0.58
ALOX12 P18054 1/20 0.58
NFKB1 P19838 1/20 0.58
HTR2A P28223 1/20 0.58
CYP2C19 P33261 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16174384 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL8230082 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL791742 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL12581063 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL12435784 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL16172571 1.00 KDM4E (0.62) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL23626333 0.81 LMNA (0.52) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL8889599 0.81 LMNA (0.52) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL517001 0.81 KDM4E (0.65) KDM4ELMNAADRA2CADRA2AHIF1A
SCHEMBL6689612 0.81 KDM4E (0.65) KDM4ELMNAADRA2CADRA2AHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022254601-A1 NANOPARTICLE-CONTAINING FILM, LIGHT-EMITTING ELEMENT, PRODUCTION METHOD FOR NANOPARTICLE-CONTAINING FILM シャープ株式会社 2022-12-08 WO disclosed
US-10851082-B2 Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) NORTHWESTERN UNIVERSITY (US) 2020-12-01 US disclosed
EP-3564235-A1 SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2) Northwestern University (US) 2019-11-06 EP disclosed
US-20170121326-A1 SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2) NORTHWESTERN UNIVERSITY (US) 2017-05-04 US disclosed
WO-2017075367-A1 SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2) NORTHWESTERN UNIVERSITY (US) 2017-05-04 WO disclosed
CN-103467730-B Carbamate compounds Asahi Kasei Chemical K. K. (JP) 2015-12-23 CN disclosed
CN-101868445-B Method for producing isocyanate and aromatic hydroxy compound ASAHI CHEMICAL CORP 2014-06-18 CN disclosed
US-8717565-B2 Optically active functional fluid markers THE LUBRIZOL CORPORATION (US) 2014-05-06 US disclosed
CN-103467730-A Carbamate compound ASAHI KASEI CHEMICAL CORP 2013-12-25 CN disclosed
EP-2376894-A1 OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS The Lubrizol Corporation (US) 2011-10-19 EP disclosed
CN-101868445-A Method for producing isocyanate and aromatic hydroxy compound ASAHI CHEMICAL CORP (JP) 2010-10-20 CN disclosed
WO-2010077753-A1 OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS THE LUBRIZOL CORPORATION (US) 2010-07-08 WO disclosed
WO-2010077754-A1 OPTICALLY ACTIVE FUNCTIONAL FLUID MARKERS THE LUBRIZOL CORPORATION (US) 2010-07-08 WO disclosed
CN-100577738-C Flame retardant resin composition POLYPLASTICS CO 2010-01-06 CN disclosed
EP-1606267-B1 PYRAZINE COMPOUNDS AS TRANSFORMING GROWTH FACTOR (TGF) INHIBITORS PFIZER PROD INC (US) 2008-07-30 EP disclosed
US-7199123-B2 Pyrazine compounds as transforming growth factor (TGF) compounds PFIZER INC. (US) 2007-04-03 US disclosed
CN-1596288-A Flame-retardant resin composition POLYPLASTICS CO (JP) 2005-03-16 CN disclosed
CN-1046507-C Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases UPJOHN CO (US) 1999-11-17 CN disclosed
CN-1139431-A Heterocyclic compounds for the treatment of central nervous system and cardiovascular diseases PHARMACIA & UPJOHN CO LLC (US) 1997-01-01 CN disclosed
US-4628120-A REARRANGEMENTS USING ORGANOALUMINUM COMPOUNDS TOYO STAUFFER CHEMICAL CO., LTD. (JP) 1986-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851082-B2 Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2) MAP4K2, MAP3K20, MKNK2 KDM4E 2527/4885LMNA 2877/4885ADRA2C 3741/4885
US-20170121326-A1 SUBSTITUTED AROMATIC N-HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MITOGEN-ACTIVATED PROTEIN KINASE INTERACTING KINASE 1 (MNK1) AND 2 (MNK2) MAP4K2, MAP3K20, MKNK2 KDM4E 2527/4885LMNA 2877/4885ADRA2C 3741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.